Program Oirector/Principal Investigator (Last, First, Middle): Bumett, John, C, Jr. PROJECT 3 Title: Maximizing the cGMP System in Preclinical Left Ventricular and Renal Dysfunction Project Description: Heart failure is a growing public health problem with high mortality and morbidity. The concept of preclinical heart failure is based on the fact that abnormal heart structure/function can be detected by complementary methods before the development of symptoms. Patients with those abnormalities may progress to symptomatic heart failure and are at increased risk of adverse cardiac events. This human translational project aims to develop novel therapeutics by maximizing the cGMP system using two FDA approved medications, Nesiritide and Tadalafil. to improve renal funcfion pafients with preclinical heart failure. Our goals are to further our understanding the cGMP pathway in the mechanism of renal dysfunction in preclinical heart failure and to develop therapies to improve the renal function with the hope of delaying the progression of preclinical heart failure to symptomatic heart failure. Project Leader: Horng H. Chen. MD;Associate Professor of Medicine Other

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL076611-07
Application #
8381101
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
Project End
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
7
Fiscal Year
2012
Total Cost
$494,451
Indirect Cost
$179,907
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Lee, Candace Y W; Huntley, Brenda K; McCormick, Daniel J et al. (2016) Cenderitide: structural requirements for the creation of a novel dual particulate guanylyl cyclase receptor agonist with renal-enhancing in vivo and ex vivo actions. Eur Heart J Cardiovasc Pharmacother 2:98-105
Mohammed, Selma F; Majure, David T; Redfield, Margaret M (2016) Zooming in on the Microvasculature in Heart Failure With Preserved Ejection Fraction. Circ Heart Fail 9:
Wan, Siu-Hin; McKie, Paul M; Schirger, John A et al. (2016) Chronic Peptide Therapy With B-Type Natriuretic Peptide in Patients With Pre-Clinical Diastolic Dysfunction (Stage B Heart Failure). JACC Heart Fail 4:539-47
Patel, Pratik A; Scott, Christopher G; Rodeheffer, Richard J et al. (2016) The Natural History of Patients With Isolated Metabolic Syndrome. Mayo Clin Proc 91:623-33
Wan, Siu-Hin; Stevens, Susanna R; Borlaug, Barry A et al. (2016) Differential Response to Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Reduced or Preserved Ejection Fraction: Results From the ROSE AHF Trial (Renal Optimization Strategies Evaluation in Acute Heart Failure). Circ Heart Fail 9:
Sangaralingham, S Jeson; Wang, Bing H; Huang, Li et al. (2016) Cardiorenal fibrosis and dysfunction in aging: Imbalance in mediators and regulators of collagen. Peptides 76:108-14
McKie, Paul M; Schirger, John A; Benike, Sherry L et al. (2016) Chronic subcutaneous brain natriuretic peptide therapy in asymptomatic systolic heart failure. Eur J Heart Fail 18:433-41
Holditch, Sara J; Schreiber, Claire A; Burnett, John C et al. (2016) Arterial Remodeling in B-Type Natriuretic Peptide Knock-Out Females. Sci Rep 6:25623
AbouEzzeddine, Omar F; French, Benjamin; Mirzoyev, Sultan A et al. (2016) From statistical significance to clinical relevance: A simple algorithm to integrate brain natriuretic peptide and the Seattle Heart Failure Model for risk stratification in heart failure. J Heart Lung Transplant 35:714-21
Holditch, Sara J; Schreiber, Claire A; Nini, Ryan et al. (2015) B-Type Natriuretic Peptide Deletion Leads to Progressive Hypertension, Associated Organ Damage, and Reduced Survival: Novel Model for Human Hypertension. Hypertension 66:199-210

Showing the most recent 10 out of 118 publications